{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:14:15Z","timestamp":1789071255624,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejphar.2026.179221","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:04:20Z","timestamp":1787209460000},"page":"179221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of renin-angiotensin system inhibitors on survival in glioma patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"1033","author":[{"given":"Junyao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-4083","authenticated-orcid":false,"given":"Tianshu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejphar.2026.179221_bib1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/sj.bjc.6602483","article-title":"Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma","volume":"92","author":"Arrieta","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.bjc.6604431","article-title":"Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis","volume":"99","author":"Arrieta","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179221_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110934","article-title":"Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression","volume":"9","author":"Azevedo","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gde.2004.12.005","article-title":"Cellular abnormalities of blood vessels as targets in cancer","volume":"15","author":"Baluk","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"20","key":"10.1016\/j.ejphar.2026.179221_bib5","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3748\/wjg.v25.i20.2524","article-title":"Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma","volume":"25","author":"Barone","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179221_bib6","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1468-1331.2012.03766.x","article-title":"Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients","volume":"19","author":"Carpentier","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12935-023-02963-1","article-title":"Antiproliferative and apoptotic effects of telmisartan in human glioma cells","volume":"23","author":"Chang","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179221_bib8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00384-014-2118-1","article-title":"Interactions of the renin-angiotensin system in colorectal cancer and metastasis","volume":"30","author":"Childers","year":"2015","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.ejphar.2026.179221_bib9","article-title":"Angiotensin converting enzyme inhibitors and lung cancer","volume":"363","author":"Cronin-Fenton","year":"2018","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179221_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1586\/14737140.2015.1028376","article-title":"Bevacizumab in high-grade gliomas: past, present, and future","volume":"15","author":"Curry","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179221_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219199120","article-title":"Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models","volume":"120","author":"Datta","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib12","first-page":"4","article-title":"Drug resistance in glioblastoma: challenges, mechanisms and therapeutic strategies","volume":"24","author":"Durga","year":"2026","journal-title":"Mol. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FJC.0000000000001600","article-title":"The potential impact of renin-angiotensin system inhibitors on cancer survival and recurrence: a systemic review and meta-analysis","volume":"85","author":"Fatima","year":"2025","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179221_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","article-title":"Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis","volume":"294","author":"Fujita","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179221_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11060-018-2802-z","article-title":"Incidence and survival of gliomatosis cerebri: a population-based cancer registration study","volume":"138","author":"Georgakis","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejphar.2026.179221_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3389\/fnins.2019.01043","article-title":"The effect of candesartan alone and its combination with estrogen on post-traumatic brain injury outcomes in female rats","volume":"13","author":"Hajmohammadi","year":"2019","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-018-2786-8","article-title":"Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?","volume":"138","author":"Happold","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejphar.2026.179221_bib18","first-page":"506","article-title":"Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer","volume":"20","author":"Hashemzehi","year":"2021","journal-title":"EXCLI J."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12935-023-03080-9","article-title":"The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies","volume":"23","author":"Hassani","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2026.179221_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2026.179221_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fphar.2017.00242","article-title":"Immune checkpoint in glioblastoma: promising and challenging","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179221_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/ene.12746","article-title":"Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma","volume":"22","author":"Januel","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179221_bib23","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma Multiforme-A literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"issue":"9\u201310","key":"10.1016\/j.ejphar.2026.179221_bib24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/07357907.2018.1544639","article-title":"Outcome of bevacizumab therapy in patients with recurrent glioblastoma treated with angiotensin system inhibitors","volume":"36","author":"Johansen","year":"2018","journal-title":"Cancer Invest."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179221_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00415-015-8016-9","article-title":"Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients","volume":"263","author":"Kourilsky","year":"2016","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179221_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-017-2528-3","article-title":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and\/or bevacizumab","volume":"134","author":"Levin","year":"2017","journal-title":"J. Neuro Oncol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179221_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030747","article-title":"Association between angiotensin-converting enzyme inhibitors and lung Cancer-A nationwide, population-based, propensity score-matched cohort study","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179221_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of Tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179221_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009327","article-title":"Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade","volume":"12","author":"Mei","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179221_bib30","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s13311-022-01251-6","article-title":"Updates in IDH-Wildtype glioblastoma","volume":"19","author":"Melhem","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179221_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"issue":"5b","key":"10.1016\/j.ejphar.2026.179221_bib32","first-page":"1985","article-title":"Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases","volume":"15","author":"Nakagawa","year":"1995","journal-title":"Anticancer Res."},{"issue":"12 Suppl. 2","key":"10.1016\/j.ejphar.2026.179221_bib33","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.ejphar.2026.179221_bib34","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"issue":"12 Suppl. 2","key":"10.1016\/j.ejphar.2026.179221_bib35","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejphar.2026.179221_bib36","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179221_bib37","first-page":"232","article-title":"Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia\/reperfusion injury in rats","volume":"18","author":"Panahpour","year":"2014","journal-title":"Iran. Biomed. J."},{"issue":"32","key":"10.1016\/j.ejphar.2026.179221_bib38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116289119","article-title":"Inhibition of the angiotensin II type 2 receptor AT(2)R is a novel therapeutic strategy for glioblastoma","volume":"119","author":"Perryman","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejphar.2026.179221_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106771","article-title":"Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model","volume":"207","author":"Pinheiro","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"17","key":"10.1016\/j.ejphar.2026.179221_bib40","doi-asserted-by":"crossref","first-page":"i430","DOI":"10.1093\/bioinformatics\/btw438","article-title":"Combining dependent P-values with an empirical adaptation of Brown's method","volume":"32","author":"Poole","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejphar.2026.179221_bib41","article-title":"The association between use of renin-angiotensin-aldosterone system inhibitors and the risk and mortality of pancreatic cancer: a systematic review and meta-analysis","author":"Rahimi","year":"2024","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179221_bib42","doi-asserted-by":"crossref","first-page":"R653","DOI":"10.1530\/ERC-19-0314","article-title":"Mechanisms linking the renin-angiotensin system, obesity, and breast cancer","volume":"26","author":"Rasha","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179221_bib43","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1054\/bjoc.2001.2102","article-title":"AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma","volume":"85","author":"Rivera","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging therapies for glioblastoma: current state and future directions","volume":"41","author":"Rong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179221_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071393","article-title":"Dexamethasone in patients with glioblastoma: a systematic review and meta-analysis","volume":"16","author":"Scheffler","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179221_bib46","article-title":"Renin-angiotensin system blockade for the risk of cancer and death","volume":"17","author":"Shen","year":"2016","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179221_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"13","key":"10.1016\/j.ejphar.2026.179221_bib48","article-title":"Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: evidence from a meta-analysis including 55 studies","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejphar.2026.179221_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.ejphar.2026.179221_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejca.2018.12.025","article-title":"Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study","volume":"109","author":"Ursu","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179221_bib51","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s13311-023-01435-8","article-title":"The renin angiotensin system as a therapeutic target in traumatic brain injury","volume":"20","author":"Villapol","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179221_bib52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1442-2050.2011.01320.x","article-title":"Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts","volume":"25","author":"Wang","year":"2012","journal-title":"Dis. Esophagus"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179221_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.13574","article-title":"Telmisartan attenuates human glioblastoma cells proliferation and oncogenicity by inducing the lipid oxidation","volume":"18","author":"Wang","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179221_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179221_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.05.015","article-title":"Renin-angiotensin system inhibitors and survival in patients with renal cell carcinoma: evidence from a meta-analysis","volume":"43","author":"Xi","year":"2025","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2026.179221_bib56","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"1","author":"Xue","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179221_bib57","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1186\/s12885-022-09919-0","article-title":"Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer","volume":"22","author":"Zeman","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2026.179221_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2017.09.007","article-title":"Captopril improves tumor nanomedicine delivery by increasing tumor blood perfusion and enlarging endothelial gaps in tumor blood vessels","volume":"410","author":"Zhang","year":"2017","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179221_bib59","first-page":"1250","article-title":"Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations","volume":"122","author":"Zhang","year":"2009","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.ejphar.2026.179221_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neuroscience.2014.04.060","article-title":"Activation of the ACE2\/Ang-(1-7)\/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction","volume":"273","author":"Zheng","year":"2014","journal-title":"Neuroscience"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600703X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600703X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:05:18Z","timestamp":1789070718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992600703X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":60,"alternative-id":["S001429992600703X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179221","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of renin-angiotensin system inhibitors on survival in glioma patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179221"}}